Intelligence · Clinical Development
Pipeline search results
Programs matching “recombinant” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 118 pipeline programs matching "recombinant" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
PEGylated recombinant human interferon alpha-2b injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatitis B, Chronic
1 trial -
Pegylated Recombinant Candida Utilis Uricase for Injection
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Gout
1 trial -
RP-A701-0125
Rocket Pharmaceuticals B.V.
Dilated Cardiomyopathy (DCM)
1 trial -
Recombinant ADAMTS13
Takeda
Hereditary Thrombotic Thrombocytopenic Purpura (TTP)
1 trial -
Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo
Shanghai University of Traditional Chinese Medicine
Healthy
1 trial -
Recombinant NV-A01 adenovirus injection
The First People's Hospital of Lianyungang
Advanced Glioblastoma Patients
1 trial -
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
COVID-19
1 trial -
Recombinant SARS-CoV-2 Fusion Protein Vaccine
Livzon Pharmaceutical Group
COVID19
1 trial -
Recombinant adeno-associated virus administration
Kunming Hope of Health Hospital
Menkes Syndrome
1 trial -
Recombinant erythropoietin stimulating protein
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Chronic Renal Failure
1 trial -
Recombinant human C1 esterase inhibitor
Takeda
Hereditary Angioedema (HAE)
1 trial -
Recombinant human arginase 1 Peg5000
International Peace Maternity and Child Health Hospital
Leukemia
1 trial -
Recombinant human hyaluronidase PH20 (rHuPH20)
HALOZYME THERAPEUTICS, INC.
Healthy
1 trial -
Recombinant human thrombopoietin
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Liver Cirrhosis
1 trial -
Recombinant human tissue kallikrein
DiaMedica Therapeutics
Stroke
1 trial -
Recombinant oncolytic herpes simplex virus type Ⅰ (R130)
Shanghai University of Traditional Chinese Medicine
Osteosarcoma
1 trial -
Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)
Takeda
Von Willebrand Disease
1 trial -
recombinant adenovirus containing the ornithine transcarbamylase gene
Ultragenyx UK Limited
Ornithine Transcarbamylase Deficiency Disease
1 trial -
recombinant human thrombopoietin injection
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Liver Disease Chronic
1 trial -
060201
Takeda
Hemophilia A
6 trials -
1838-009
HALOZYME THERAPEUTICS, INC.
Dehydration
1 trial -
2018ZX10721202001002001
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatitis B Vaccine
3 trials -
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
BioMarin Pharmaceutical Australia Pty Ltd
Mucopolysaccharidosis I
3 trials -
Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
Takeda
Hemophilia A
4 trials
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.